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E55 murine leukemia retrovirus (E55MuLV) infection of young and aged C57BL/6 (B6) mice was used to investigate the
relationship between increased incidences of infection and decreased immune responsiveness of elderly individuals. Young
mice decreased E55MuLV burden to below detectable levels by 8 weeks postinfection (p.i.). In contrast, virus burden in
aged mice did not reach undetectable levels until 20 weeks p.i. A significant T cell proliferative response to E55MuLV was
detected from 2 to 12 weeks p.i. in young mice, but was never observed in aged mice. Both age groups demonstrated
significant E55MuLV-specific T-cell-mediated cytotoxic responses at 3 and 4 weeks p.i. and virus neutralizing antibody
titers at 2, 4, 8, and 12 weeks p.i. In both cases, responses were consistently higher in young mice (P  0.04 and P  0.02,
respectively). These results demonstrate that the observed delay in E55MuLV clearance by aged mice is associated with
an age-related decrease in the immune response to the virus. © 2001 Academic Press
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INTRODUCTION
Epidemiologic data show that aging is associated with
an increased incidence of virus infections. In addition,
there is increased morbidity and mortality among the
elderly as a result of these infections (Felser and Raff,
1983). For example, age is an important predictor of
progression of HIV disease. Older patients infected with
HIV not only develop AIDS faster than younger patients,
they die more quickly after developing an AIDS-defining
illness (Ship et al., 1991; Adler and Nagel, 1994; Adler et
al., 1997). Although it has been shown that aging is
associated with alterations in both T-cell-mediated im-
munity (Kirschmann and Murasko, 1992; Goonewardene
and Murasko, 1994; Chakravarti and Abraham, 1999;
Pawelec et al., 1999) and humoral immunity (LeMaoult et
al., 1997; Song et al., 1997), few studies have examined
directly the relationship between decreased immune re-
sponsiveness and diminished control of virus infections
in the aged.
E55 murine leukemia virus (E55MuLV) is a repli-
cation-competent murine retrovirus that causes leuke-
mia in susceptible strains of mice (BALB) after a long
latent period (Tumas et al., 1993a). In contrast, infection
of resistant strains of mice (C57BL) fails to progress to
leukemia even though E55MuLV establishes a persis-
tent infection in both strains of mice (Avidan et al., 1995).
Infection of both resistant and susceptible mice is char-
acterized by an acute phase and a persistent phase. The
acute phase is characterized by the presence of large
numbers of virus-infected cells in spleen and bone mar-
row during the first 2–4 weeks postinfection (p.i.). The
number of virus-infected cells decreases to undetectable
levels by 8 weeks p.i. due to the generation of an anti-
virus immune response. The anti-virus immune response
has been demonstrated to play an important role in
controlling virus infection during this acute phase be-
cause mice irradiated sublethally prior to inoculation
with E55MuLV show no decrease in virus burden (Avi-
dan et al., 1995; Panoutsakopoulou et al., 1998). However,
despite the immune response, the virus is not eradicated
with the infected cells sequestered in the lymphoid tis-
sue (Tumas et al., 1993b; Avidan et al., 1995). During the
persistent phase, BALB strains of mice demonstrate an
increase in virus-infected cells at about 5–8 months p.i.
that correlates with the development of leukemia. In
contrast, no increase in infected cells occurs in C57BL
strains of mice (Tumas et al., 1993b; Avidan et al., 1995;
Panoutsakopoulou et al., 1998).
Due to the importance of the anti-virus immune re-
sponse in the control of E55MuLV burden during the
acute phase of infection, we utilized this model to directly
test the hypothesis that decreased immune responsive-
ness with aging is associated with impaired virus clear-
ance during the acute phase of infection. The present
studies demonstrate that, unlike young C57BL/6 (B6)
mice that decreased E55MuLV burden by 8 weeks p.i.,
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aged B6 mice showed a delay in virus clearance. This
delay in virus clearance in aged mice was associated
with the lack of a T cell proliferative response, a signif-
icantly lower cytotoxic T cell response to E55MuLV,
and significantly lower virus neutralizing antibody titers
in aged mice than in young mice. These results suggest
that the observed difference between young and aged
mice in E55MuLV clearance is associated with, and
possibly due to, age-related alterations in both T and B
cell responses to the virus.
RESULTS
Clearance of E55MuLV in 6- and 22-month-old B6
mice
Although previous studies in this laboratory have dem-
onstrated that 8-week-old B6 mice inoculated with
E55MuLV were able to decrease virus burden to un-
detectable levels by 8 weeks p.i. (Panoutsakopoulou et
al., 1998), the effect of age on control of E55MuLV had
not been examined. We therefore assessed the ability of
6- (young) and 22- (aged) month-old B6 mice to decrease
virus burden during the acute phase of E55MuLV in-
fection. Mice were inoculated with E55MuLV and
splenic virus titers were determined by fluorescent focus
assay (FFA) at various times p.i. Both age groups ex-
pressed comparable levels of virus at 2 and 4 weeks p.i.
(Table 1). However, by 8 weeks p.i., young mice de-
creased virus burden to undetectable levels, while aged
mice continued to express high levels of virus in spleen.
While virus titers were still detectable at 12 (Table 1) and
16 weeks p.i. (data not shown), aged mice finally de-
creased virus burden to undetectable levels by 20 weeks
p.i. These data suggest that while 6-month-old mice
expressed an infection profile similar to that of 8-week-
old mice, the ability of 22-month-old mice to clear
E55MuLV was delayed considerably.
T cell proliferative and cytotoxic responses to
E55MuLV of young and aged B6 mice
To determine whether the observed difference in virus
clearance between the two age groups was due to an
age-associated alteration in the adaptive immune sys-
tem, spleen cells from young and aged B6 mice infected
with E55MuLV were used in proliferation and cytotoxic
T lymphocyte (CTL) assays at various times p.i. Spleno-
cytes of young mice generated a significant proliferative
response to E55MuLV at 2 and 4 weeks p.i. that was
maintained at 8 and 12 weeks p.i. (Fig. 1). In contrast,
splenocytes of aged mice failed to generate a significant
proliferative response to E55MuLV at any time exam-
ined. CD4 T cells were required to obtain a significant
proliferative response in young mice because in vitro
depletion of these cells prior to stimulation completely
abolished this response (data not shown). Depletion of
CD8 T cells prior to stimulation decreased the level of
responses by 10–20%, which was not a statistically sig-
nificant reduction (data not shown).
Virus-specific CTL activity was first detected in both
TABLE 1
E55 Virus Production in Young and Aged C57BL/6 Micea
Age
(months)
Weeks postinfection
2 4 8 12 20
6 1 103 1 105 10 10 ND
(10–3 103) (4 103–5 105)
22 1.3 103 8.3 104 4.9 105 2 103 10
(2 102–3 103) (1 103–3 105) (2 102–2 106) (2 101–1 104)
Note. Mean virus titers of 6–8 mice/time point expressed as FFU/ml of 10% spleen homogenate. Numbers in parentheses are the range of results.
ND, not done.
a The level of infectious virus in the spleen of B6 mice was quantified by FFA at various times postinfection.
FIG. 1. T cell proliferative response to E55MuLV in young and aged
mice. Spleen cells from individual naive or E55MuLV-infected B6
mice, at 2, 4, 8, and 12 weeks p.i. were cultured with either naive or
E55MuLV-infected IC21 cells. Proliferation is expressed as net counts
per minute (Net CPM). Values are means  SEM of 6–12 individual
mice assayed in three separate experiments, 2–4 mice/group/experi-
ment. Values of the control group (spleen cells cultured with uninfected
IC21 cells) are means  SEM of all time points tested. Statistically
significant differences as determined by Student’s t test; * naive vs
infected IC21 cells, P  0.02; # young vs aged of same time point, P 
0.05 ANOVA analysis of all time points of one age group demonstrated
no statistically significant differences.
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age groups at 3 weeks p.i. (Fig. 2A), with the peak
virus-specific CTL activity being detected at 4 weeks p.i.
(Fig. 2B). By 8 weeks p.i. the CTL response was unde-
tectable in both age groups and remained undetectable
at 12 weeks (data not shown). Although the kinetics of
virus-specific CTL response were comparable in both
age groups, the CTL response was consistently and
significantly higher in young mice (P  0.04). CD8 T
cells mediated cytotoxicity in both age groups because
in vitro depletion of these cells prior to assay completely
abrogated the CTL response (Fig. 2B).
Role of B cells in clearance of E55MuLV in young
mice
B cells play a crucial role in the clearance of some
primary virus infections (Bachmann and Kopf, 1999).
While B-cell-deficient mice (MT) showed decreased
resistance to Friend virus (FV)-induced splenomegaly,
suggesting that B cells are required for the control of FV
infection (Hasenkrug, 1999), the role of B cells in control
of E55MuLV infection was unknown. To address this
question, 8-week-old MT mice were inoculated with
E55MuLV and splenic virus titers were determined by
FFA at 8 weeks p.i. Unlike intact B6 mice, MTmice were
unable to lower the virus burden by 8 weeks p.i. even
after inoculation with a 10-fold lower dose of E55MuLV
(Table 2). In fact, the MT mice expressed virus levels
comparable to virus titers in irradiated B6 mice. These
results suggest that B cells play a role in decreasing
virus burden by 8 weeks p.i. in young B6 mice.
Virus-neutralizing antibody titers in young and aged
B6 mice
Since our data suggested that B cells are required for
decreasing virus burden by 8 weeks p.i. in young mice,
we measured the E55MuLV-specific neutralizing anti-
body (Ab) titers in sera of young and aged B6 mice at
various times p.i. All B6 mice were pre-bled, inoculated
with E55MuLV, and bled again at 2, 4, 8, or 12 weeks
p.i. The sera were then evaluated by virus neutralization
assay. The results show that at 2 weeks p.i., 8 of 10
young mice and only 1 of 10 aged mice had detectable
Ab titers (Fig. 3). At 4 weeks p.i. all young mice tested (15
mice) had detectable Ab titers; 15 of 17 aged mice had
detectable Ab titers. Although mean Ab titers were sig-
nificantly higher at 4 weeks p.i. than at 2 weeks p.i. in
both age groups (P  0.0005), young mice had signif-
icantly higher mean Ab titers than aged mice at 4 weeks
p.i. (P  0.02; Fig. 3). All mice tested at 8 weeks p.i. (12
mice/age group) had detectable Ab titers, but young
mice still had significantly higher mean Ab titers than
aged mice. Similar results were obtained at 12 weeks
p.i., except that only 7 of 9 aged mice tested had detect-
able Ab titers while all young mice (9 mice) had detect-
able Ab titers. Collectively, these results indicate that
aged mice demonstrate both a delay in the generation of
virus-neutralizing antibodies and significantly lower
mean Ab titers compared to young B6 mice.
FIG. 2. E55MuLV-specific cytotoxic T cell response of young and
aged B6 mice. Pooled spleen cells from 3–4 naive (‚) or E55MuLV-
infected young (}) and aged () B6 mice at 3 (A) and 4 (B) weeks p.i.
were used as effector cells in a CTL assay against uninfected and
virus-infected IC21 cells (H-2b). Aliquots of spleen cells were depleted
of CD8 T cells prior to assay (x,). Cytotoxicity of both KKC (H-2k) and
uninfected IC21 cells was 5% at all E:T ratios. The data shown are
means  SEM of three separate experiments. Statistically significant
differences as determined by Student’s t test; * young vs aged, P 
0.04, # aged vs naive, P  0.02.
TABLE 2
E55 Virus Production in MT Micea
Dose of virus
(FFU)
Recipient mice
C57BL/6
Irradiated C57BL/6
(450 rad/mouse)
C57BL/6-Igh
(MT)
4 104 10 3 102 2 102
10 2 102 2 103
10 3 102 3 101
4 103 10 3 101 1 103
10 1 102 1 102
10 4 101 1 102
a Eight-week-old mice were infected with either the standard dose or
a 10-fold lower dose of E55MuLV. All mice were sacrificed at 8 weeks
p.i. and virus titers were determined by FFA. Titers were expressed as
FFU/ml of 10% spleen homogenate.
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Although antibody was determined to be required for
control of E55MuLV infection in young MT (Table 2),
antibody alone did not seem to be sufficient for control of
E55MuLV in aged mice. Five aged mice were as-
sessed for both virus titers and neutralizing antibody
titers at 12 weeks postinfection. While all five mice had
detectable virus titers (102–104 focus-forming units (FFU)/
ml), two of the five mice had high antibody titers, one had
low antibody, and two had no detectable antibody. Of the
two mice with virus titers of 104, one had no antibody
while one had high antibody (data not shown).
DISCUSSION
The increased incidence and severity of virus infec-
tions that occur with increasing age have been attributed
to an age-associated alteration(s) in specific immune
responses (Schneider, 1983; Louria et al., 1993). While
many studies have demonstrated that aging is associ-
ated with alterations in T and B cell function (Kirschmann
and Murasko, 1992; Goonewardene and Murasko, 1994;
Chakravarti and Abraham, 1999; Pawelec et al., 1999;
LeMaoult et al., 1997; Song et al., 1997), only a limited
number of studies have examined the association be-
tween decreased immune responsiveness and dimin-
ished control of primary virus infections in the aged
(Jacoby et al., 1994; Bender et al., 1995). In the current
studies we have characterized a model that could be
used to investigate further this relationship.
Previous studies in this laboratory have demonstrated
that E55MuLV infection of young B6 mice is character-
ized by the presence of large numbers of virus-infected
cells in the spleen and bone marrow during the first 2–4
weeks p.i. The generation of an anti-virus immune re-
sponse plays a crucial role in decreasing virus burden to
undetectable levels by 8 weeks p.i. (Panoutsakopoulou
et al., 1998; Avidan et al., 1995). We hypothesized that an
age-associated decrease in the immune response
against E55MuLV would lead to failure of the aged
mice to decrease virus burden by 8 weeks p.i. Our
results clearly show that the spleens of aged B6 mice
continued to express detectable levels of E55MuLV at
8 and 12 weeks p.i., while virus was undetectable in
young B6 mice. Although we expected virus titers to
persist throughout the remaining life span of aged mice,
we found that aged mice were able to decrease virus
burden to undetectable levels by 20 weeks p.i. This delay
in the ability of aged mice to clear E55MuLV is similar
to results with influenza virus. Unlike young mice that
stopped shedding virus by 7–8 days p.i., aged mice
continued to retain virus in their lungs for 12–13 days p.i.
(Bender et al., 1991, 1995). These results are consistent
with the observation that elderly individuals have a pro-
longed duration of illness following viral infections.
CD4 T cells play an important role in the control of
some virus infections. In the closely related FV system, in
vivo depletion of CD4 T cells prior to infection resulted
in a dramatic increase in splenomegaly and mortality of
FV-infected mice by 60–90 days p.i. (Robertson et al.,
1992). Similarly, in vivo depletion of CD4 T cells prior to
mouse poxvirus (MPV) infection resulted in a significant
increase in splenic and liver virus titers and incomplete
virus clearance (Karupiah et al., 1996). Previous studies
in this laboratory have demonstrated the importance of
CD4 T cells in the control of E55MuLV infection in
young mice. In vivo CD4 T cell depletion prior to
E55MuLV inoculation of young B6 mice completely
FIG. 3. E55MuLV neutralizing antibody titers of young and aged B6 mice. Young and aged B6 mice were infected with E55MuLV. Antibody titers
were determined for individual mice at 2, 4, 8, and 12 weeks p.i. Data are from three separate experiments (3–6 mice/group/experiment). Bars
represent the mean log2 titer/group. Statistically significant differences as determined by Student’s t test: young vs aged, P  0.02 at all times; 2
weeks vs 4 weeks p.i., P  0.0005 in both age groups.
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abrogated their ability to decrease virus burden during
the acute phase of infection (Panoutsakopoulou et al.,
1998). In this system, CD4 T cells were able to mediate
reduction of virus burden in the absence of CD8 T cells
since in vivo CD8 T cell depletion did not affect the
ability of the 8-week-old mice to decrease virus burden
(Panoutsakopoulou et al., 1998).
In the current studies, the proliferative response of T
cells to E55MuLV was examined in young and aged
mice. Both young and aged mice expressed comparable
levels of virus in spleen at 2 and 4 weeks p.i. However,
only splenocytes of young mice generated a significant
proliferative response to E55MuLV. This response was
dependent on CD4 T cells since depletion of CD4 cells
prior to culture abrogated all reactivity, while depletion of
CD8 cells prior to culture reduced the proliferative re-
sponse only 10–20%. Importantly, the proliferative re-
sponse of young mice was detected as early as 2 weeks
p.i. and was maintained at 12 weeks p.i., a time when the
virus had been reduced. In contrast, aged mice never
achieved a significant proliferative response to E55MuLV
at any of the times tested.
CTL activity plays a key role in the clearance of many
virus infections. For example, in vivo depletion of CD8 T
cells during primary simian immunodeficiency virus in-
fection resulted in higher plasma viral RNA levels and
higher levels of virus replication compared to the control
group (Schmitz et al., 1999). Similarly, in vivo depletion of
CD8 T cells prior to FV infection resulted in 75% of mice
dying or developing splenomegaly by 60–90 days p.i.
compared to 10% of control mice (Robertson et al.,
1992). Depletion of CD8 T cells prior to infection with a
dose of MPV that was nonlethal in intact mice resulted in
100% mortality (Karupiah et al., 1996). Furthermore, influ-
enza virus infection of mice lacking class I major histo-
compatibility complex (MHC)-restricted T cells (2-M
/)
(Bender et al., 1992) or of MT mice depleted of CD4 T
cells (Riberdy et al., 2000) has indicated that CD8 T
cells were necessary, and in some situations sufficient,
for termination of influenza virus infection.
Based on this evidence, we examined E55MuLV-
specific CTL activity. The kinetics of E55MuLV-specific
CTL activity was similar in both young and aged mice.
Although virus-specific CTL activity was not detectable at
2 weeks p.i., CTL activity increased by 3 weeks p.i.,
peaked at 4 weeks p.i., and declined to undetectable
levels by 8 weeks p.i. CTL activity, however, was signif-
icantly higher in young mice than in aged mice at all time
points (P  0.04). Previous studies using the influenza
virus model found that prolonged virus shedding in aged
mice correlated with a 5- to 7-day delay in the generation
of splenic anti-influenza CTL (Bender et al., 1991) and a
1-day delay in the generation of pulmonary anti-influenza
CTL activity (Bender et al., 1995). While the delay in
influenza virus clearance in aged mice appeared to be
associated with a delay in generation of CTL activity, the
delay in clearance of E55MuLV may depend on an
age-associated shift in the mechanism of immune con-
trol of virus infection. In young mice, CD4 T cells can
mediate reduction in E55MuLV titers in the absence of
CD8 T cells (Panoutsakopoulou et al., 1998). Since aged
mice demonstrate no statistically significant CD4 T cell
reactivity in vitro as assayed by proliferation, the eventual
reduction in E55MuLV titers may require CD8 T cells
with little or no assistance from CD4 T cells.
The decline in E55MuLV-specific CTL activity in
aged mice may be due to an alteration in intrinsic CD8
T cell function. Alternatively, the observed decrease in
E55MuLV-specific CTL activity in aged mice may be
due to age-related changes in the CD4 T-helper cells
that may provide immunologic support for CTL. Reports
on the requirements for CD4 T cell help for the gener-
ation of class I MHC-restricted antiviral CTL responses
are controversial. Impaired CTL responses to vesicular
stomatitis virus (VSV) and lymphocytic choriomeningitis
virus (LCMV) occurred in mice depleted in vivo of CD4
T cells prior to virus inoculation (Leist et al., 1989). Ad-
ditional studies using MHC class II-deficient mice have
found that VSV-specific primary CTL response was ab-
sent, while LCMV-specific primary CTL response was
reduced (Battegay et al., 1996) in infected mice. Similarly,
in vivo depletion of CD4 T cells prior to MPV inoculation
resulted in the generation of suboptimal virus-specific
CTL at day 8 p.i. compared to control monoclonal anti-
body (mAb) treated mice (Karupiah et al., 1996). In con-
trast, other studies using similar antibody depletion ap-
proaches have shown that CD4 T cells were not re-
quired for the generation of CTL responses against MPV
(Buller et al., 1987), LCMV (Ahmed et al., 1988), and
influenza (Riberdy et al., 2000). Since our results showed
an alteration in CD4 T cell function in aged mice, the
possibility remains that the observed decrease in CTL
activity in aged mice may have been due to age-related
decline in both CD4 and CD8 T cell functions.
B cells also play a crucial role in the clearance of
some viral infections. Polyoma virus (PyV) infection of
SCID mice, which lack functional B and T cells, resulted
in fatal acute myeloproliferative disease within 14–16
days p.i. in 100% of mice. In contrast, PyV infection of
T-cell-deficient mice (TCR / /), which had tar-
geted disruption of their TCR  and  genes, resulted in
100% survival, regardless of the presence or absence of
NK cells (Szomolanyi-Tsuda and Welsh, 1996). In another
study, athymic nude mice and TCR / / mice
were able to clear primary rotavirus infection, while only
40% of SCID mice cleared all intestinal virus (Franco and
Greenberg, 1997). This study suggests that B cells, pos-
sibly with some innate immune mechanisms, can clear
rotavirus. In some systems, B cells were found to be
required for control of virus infections only in specific
situations. For example, in mice resistant to FV infection
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due to the FV-2 gene, B cell deficiency (MT /) had
only a limited effect on splenomegaly (Hasenkrug, 1999),
while depletion of B cells in susceptible mice always
results in the development of erythroleukemia (Doig and
Cheeseboro, 1979). Similarly, MT mice were more sus-
ceptible to influenza as demonstrated by a 50- to 100-fold
reduction in the LD50 (Graham and Braciale, 1997). How-
ever, when MT mice are infected with a dose of virus
that is nonlethal, virus clearance occurs and is depen-
dent on CD8 T cells (Riberly et al., 2000).
We utilized MT mice to examine the role of B cells in
the control of E55MuLV infection in young B6 mice.
Young MT mice were unable to decrease E55MuLV
burden by 8 weeks p.i., even after inoculation with a
10-fold lower dose of virus. They expressed virus levels
comparable to virus titers of irradiated–infected B6 mice.
Since these results suggested that B cells are required
for early clearance of E55MuLV in young mice, we
determined the differences in virus-neutralizing Ab titers
between young and aged B6 mice at various times p.i. A
delay in the generation of virus-neutralizing Ab was ob-
served in aged mice. In addition, young mice had signif-
icantly higher Ab titers than aged mice at all times tested.
These results are consistent with other observations that
show that the antibody response to T-cell-dependent
foreign antigens decreases dramatically with age (Goidl
et al., 1976).
The age-related decrease in anti-E55MuLV antibody
titers may be due to an intrinsic alteration in B cell
function. Alternatively, since activated CD4 T-helper
cells provide immunologic support for B cells, and our
results suggest an alteration in CD4 T cell function in
aged mice, the observed decrease in virus-neutralizing
Ab titers in aged mice may have occurred because the
aged CD4 T cells provided less efficient help to the B
cells. In young FV-infected mice, CD4 T cells are re-
quired for production of virus-neutralizing antibodies
since CD4 T-cell-depleted mice lacked detectable FV-
neutralizing antibodies at 30 days p.i. (Super et al., 1998).
Similarly, in other studies using mice transgenic for the
human poliovirus receptor, the adoptive transfer of both
poliovirus-specific CD4 T and B cells, but not either cell
type alone, was required to confer protection following
challenge with a virulent strain of poliovirus (Mahon et
al., 1995).
In summary, E55MuLV provides a unique model by
which age-associated changes in the anti-virus immune
response can be studied. The long acute phase of virus
expression allows careful evaluation of the role of alter-
ations in the kinetics of immune response on control of
virus. The reexpression of E55MuLV in persistently
infected susceptible mice allows the examination of the
role of the level and type of immune response required
for maintenance of this control. Lack of reexpression of
E55MuLV in persistently infected aged mice of the
resistant strain would suggest that control requires a
fairly limited immune response. In addition, following
infected young mice of the resistant strain for a longer
period of time will determine whether the natural decline
in immune responses that occurs with aging will result in
reemergence of the virus and progression to leukemia.
We are currently utilizing this model to assess differ-
ences in the cytokine profiles of young and aged mice
during the acute phase of E55MuLV infection. We will
also determine whether adoptive transfer of cells from
young mice can alter the pattern of E55MuLV clear-
ance in aged mice.
MATERIALS AND METHODS
Mice
Six- and 22-month-old C57BL/6 (B6) male mice were
purchased from the NIA colony of Charles River Labora-
tories. Eight-week-old MT (C57BL/6-Igh-6tm1Cgn) and B6
mice were purchased from The Jackson Laboratories
(Bar Harbor, ME). All mice were housed in AAALAC-
certified barrier facilities at MCP Hahnemann University
and were given autoclaved food and water ad libitum.
Mice were allowed to acclimate for at least 2 weeks in
our facilities prior to use. Mice demonstrating tumors of
any kind were eliminated from the study.
Virus
E55 murine leukemia virus was originally isolated
from a BALB.K spleen injected with cell-free culture su-
pernatant from a T cell line derived from a leukemic
mouse (Pozsgay et al., 1989). The virus used in these
studies was propagated in vivo by intraperitoneal (ip)
injections of immunosuppressed BALB/c mice (Wolf and
Blank, 1983). All mice used in the studies were injected
ip with 4  104 FFU of E55MuLV, unless indicated
otherwise.
Antibodies
Hybridoma cells producing the monoclonal antibodies
mAb34, specific for the p15-gag protein, and mAb48,
specific for the gp70 envelope protein (Cheseboro et al.,
1981), were a gift from Dr. Bruce Cheseboro. Hybridoma
cells producing the mAb GK1.5 (anti-CD4) and 2.43 (anti-
CD8) were obtained from American Type Culture Collec-
tion (ATCC; Rockville, MD). Antibodies were purified us-
ing protein A–Sepharose affinity chromatography (Ey et
al., 1978).
Cells
The IC21 cell line is an SV40-transformed macrophage
line derived from peritoneal macrophages of normal B6
mice and was obtained from ATCC. IC21 cells express
class I (H-2b) and class II (I-Ab) MHC molecules.
E55MuLV-infected IC21 cells express viral epitopes of
the env and gag gene products, as determined by flow
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cytometric staining with mAb34 and mAb48. The KKC
tumor cell line (H-2k, class I positive and class II nega-
tive) was established in our laboratory from the leukemic
spleen of an immunosuppressed (550 rad) BALB/c-H-2k
(BALB.K) mouse inoculated with E55MuLV. KKC and
IC21 cells were maintained in RPMI 1640 (Media Tech,
Herndon, VA) with 10% FCS (Sigma, St. Louis, MO), 1 mM
L-glutamate, 100 U penicillin, 0.1 mg streptomycin, and
5  105 M 2-mercaptoethanol (complete medium). The
Mus dunni fibroblast cell line was a gift from Dr. Harvey
Schlesinger and was maintained in DMEM (Media Tech)
with 10% FCS, 1 mM L-glutamate, 100 U penicillin, and 0.1
mg streptomycin (maintenance medium).
Fluorescent focus assay
FFA was performed as previously described (Sitbon et
al., 1985). Briefly, M. dunni cells were plated at 6  103
cells/well in 24-well plates in maintenance medium with
10 g polybrene/ml (Sigma). Cells were infected with
serial 10-fold dilutions of spleen homogenates. One hour
after infection, wells were washed with PBS and fresh
maintenance medium was added. Cells were cultured
for 3–4 days until confluent. Cells were washed with PBS,
stained with mAb34 for 1 h at 4°C, and then stained with
FITC-conjugated anti-mouse Ig antibody (Southern Bio-
technology, Birmingham, AL) for 1 h at 4°C. After being
washed with PBS, the fluorescent foci were counted
using an inverted fluorescence microscope (Zeiss-IM,
Germany). Virus titers were expressed as fluorescent
FFU per milliliter of spleen homogenate. Although the
FFA can detect 1 FFU/ml, the spleens were a 10% ho-
mogenate and, therefore, the sensitivity of this assay is
10 FFU/ml of homogenate.
T cell proliferation assay
Spleen cells from individual naive or E55MuLV-in-
fected B6 mice were harvested at various times starting
at 2 weeks p.i. and were cultured in complete medium in
96-well plates at 1  105 cells/well in the presence of
2.5  104 naive or E55MuLV-infected IC21 cells. IC21
cells were treated with mitomycin C (50 ng/ml) for 1 h at
37°C and then washed 3–4 times with PBS before use.
Splenocytes were cultured for 72 h and pulsed with 1.0
Ci [3H]thymidine per well during the final 12 h of culture.
Cells were harvested using a PHD cell harvester (Cam-
bridge Technologies, Cambridge, MA) and radioactivity
was counted in a liquid scintillation counter (Beckman,
Columbia, MD). Proliferation is expressed as net counts
per minute (cpm) calculated as:
Net cpm cpm of splenocytes with IC21 cells
 cpm of splenocytes alone.
Cell-mediated cytotoxicity assay
Pooled spleen cells from three or four naive or
E55MuLV-infected B6 mice were harvested at various
times starting at 2 weeks p.i. and were cultured in 24-
well plates at 8 106 cells/well with 1 106 E55MuLV-
infected IC21 cells. Virus-infected IC21 cells were treated
with mitomycin as described above. Mixtures were cul-
tured for 5 days in complete medium at 37°C in 5% CO2.
Cells were then washed, counted, resuspended in com-
plete medium, and used as effectors in the JAM assay
(Matzinger, 1991). Briefly, target cells (naive or
E55MuLV-infected IC21 cells, or KKC cells) were
pulsed with 3–4 Ci [3H]thymidine for 6 h, washed, and
then plated at 1  104 cells/well in round-bottom 96-well
plates. Effectors and targets were incubated at various
E:T ratios for 4 h and then harvested using a PHD cell
harvester. Retained radioactivity was counted in a liquid
scintillation counter. In some cases, the effector cells
were depleted in vitro of CD8 T cells with antibody and
complement before addition to the target cells as previ-
ously described (Panoutsakopoulou et al., 1998). Per-
centage specific lysis was calculated as
Percentage Lysis 	S  E/S
 	 100,
where S (spontaneous) is retained 3H in the absence of
effectors and E (experimental) is retained 3H in the pres-
ence of effectors. Cytotoxicity of both uninfected IC21
and H-2 incompatible KKC (H-2k) target cells by effector
cells from E55MuLV-infected mice was consistently
5% at all E:T ratios.
Virus neutralization assay
Serial twofold dilutions of sera from individual naive or
E55MuLV-infected mice were incubated with 5  102
FFU of E55MuLV for 1 h at 37°C in 5% CO2. As negative
controls, virus was incubated either with medium alone
or with serial dilutions of immune sera from herpes
simplex virus-infected mice. The serum–virus mixture
was then added to previously plated M. dunni cells in
24-well plates and FFA was performed as described
above. The virus-neutralizing antibody titer was defined
as the reciprocal of the highest dilution of serum that
completely inhibited E55MuLV infection of M. dunni
cells. As a positive control, anti-gp 70 polyclonal antibody
(Quality Biotech Inc., Camden, NJ) was used in every
assay and consistently had an antibody titer of 1:160. All
results are presented as log2 of the titer.
Statistical analysis
Data are presented as means  SEM. All statistics
were performed using JMP software version 3.2.6 (SAS
Institute). Statistical significance between groups was
determined using either unpaired Student’s t test or an
ANOVA.
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